公开(公告)号：US20200071403A1

公开(公告)日：2020-03-05

申请号：US16687387

申请日：2019-11-18

Applicant: I-MAB Biopharma US Limited

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang ,  Wenqing Jiang ,  Yongqiang Wang

IPC: C07K16/28 ,  A61K35/17 ,  A61P37/04 ,  A61P35/00

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

公开(公告)号：US20220119531A1

公开(公告)日：2022-04-21

申请号：US17563502

申请日：2021-12-28

Applicant: I-Mab Biopharma US Limited

Inventor： Lei Fang ,  Yongqiang Wang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

公开(公告)号：US11414485B2

公开(公告)日：2022-08-16

申请号：US16687387

申请日：2019-11-18

Applicant: I-MAB Biopharma US Limited

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang ,  Wenqing Jiang ,  Yongqiang Wang

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/04 ,  A61K35/17 ,  A61K39/00

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.